Glucose-Lowering Drugs and Primary Prevention of Chronic Kidney Disease in Type 2 Diabetes Patients: A Real-World Primary Care Study
<b>Background/Objectives:</b> The burden of chronic kidney disease (CKD) is increasing, as is the prevalence of type 2 diabetes mellitus (T2DM). Post-hoc analyses of clinical trials support that sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptors ago...
Saved in:
Main Authors: | Antonio Rodríguez-Miguel (Author), Beatriz Fernández-Fernández (Author), Alberto Ortiz (Author), Miguel Gil (Author), Sara Rodríguez-Martín (Author), Gema Ruiz-Hurtado (Author), Encarnación Fernández-Antón (Author), Luis M. Ruilope (Author), Francisco J. de Abajo (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2024-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China
by: Xiang Xiao, et al.
Published: (2024) -
Real-World Data Study on Risk Factors Associated with Acute Kidney Damage in Patients Treated with Anti-MRSA Antibiotics
by: Ivan Maray, et al.
Published: (2024) -
Finerenone Attenuates Endothelial Dysfunction and Albuminuria in a Chronic Kidney Disease Model by a Reduction in Oxidative Stress
by: Raquel González-Blázquez, et al.
Published: (2018) -
Clinical pharmacology facing the real-world setting: Pharmacovigilance, pharmacoepidemiology and the economic evaluation of drugs
by: Antonia Agustí, et al.
Published: (2023) -
A Real Saline Challenge: Diagnosing Primary Aldosteronism in the Setting of Chronic Kidney Disease
by: Sasan Mirfakhraee MD, et al.
Published: (2021)